GSTC
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. The company was incorporated in 2016 and is based in Richland, Washington.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2024 Q3 | -0.00 | $0 | -$20,404 |
| 2024 Q2 | -0.00 | $0 | -$12,384 |
| 2023 Q1 | -0.00 | $0 | -$42,800 |
| 2023 Q4 | -0.00 | $0 | -$72,695 |
| 2023 Q3 | -0.00 | $0 | -$40,176 |
| 2023 Q2 | -0.00 | $0 | -$53,747 |
| 2022 Q1 | -0.00 | $0 | -$39,142 |
| 2022 Q4 | -0.00 | $0 | -$38,647 |